APP surges 47% in 3 months as Axon 2 drives $10B ad spend and record profits. Does the rally still have room to run?

Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

The United States market has seen a positive trend, climbing by 2.1% over the past week and rising 14% over the past year, with earnings forecasted to grow by 15% annually. In this environment, ...

Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Alta Advisers boosted its Amgen stake by nearly 50% this quarter, owning shares worth $844,000 at last count. Vanguard, ...